The Servier Research Group and Vernalis announce they have achieved a research milestone in their threeyear oncology drug discovery collaboration initiated in May 2009. This is the second collaboration between Servier and Vernalis, the first collaboration is focused on developing two promising oncology targets involved in protein-protein interactions.
Emmanuel Canet, MD, PhD, President Servier Research and Development, added: “We are very satisfied with this collaboration reaching an important milestone on a truly innovative oncology target. This is a step further in our aim to finalise the discovery of innovative compounds with potential use in therapeutic indications with high unmet medical need. Cancer represents a major cause of mortality worldwide and Servier is committed to providing patients with novel therapeutic approaches for treating this devastating disease.
Vernalis is an English biotech company which has a high-level technical background and recognised expertise in research and development.
Vernalis official website : vernalis.com